Article

Quantel Medical expands in U.S. market

Quantel Medical, which develops and markets diagnostic ocular ultrasound systems and surgical lasers, has expanded its U.S. operation.

Bozeman, MT-Quantel Medical, which develops and markets diagnostic ocular ultrasound systems and surgical lasers, has expanded its U.S. operation.

The company, founded in 1993 in Clermont-Ferrand, France, said it hopes to use its U.S. organization in Bozeman, MT, to increase brand recognition within the U.S. eye-care industry and to facilitate product integration and innovation in the U.S. market as a whole.

“Quantel’s ophthalmology business has been growing in excess of 20% per year for each of the past 3 years, driven by new product introductions and good customer service,” said Peter Falzon, general manager of the Quantel USA Inc. medical division. “Our strategy to invest more in the U.S. market will result in more sales, marketing, training, and technical resources in the field to support our customers.”

Recent additions to the product line include an ultrasound platform offering seven probes, including a 50-MHz ultrasound biomicroscopy probe, and a photocoagulator platform that offers pattern-scanning and micropulse technology.

“Quantel is uniquely positioned in today’s ophthalmology market for three reasons: Our well-recognized and reputable name in ophthalmology, our presence in 85 countries around the world, and our capacity to develop and commercialize innovative products quickly,” said Jean-Marc Gendre, chief executive officer. “We are looking forward to establishing a wider customer base in the United States.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.